Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ORAMED PHARMACEUTICALS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.64
2.46
2.45
2.7
2.71
2.7
2.7
1.34
2
Cost of revenue
0.49
0.19
-0.09
0.09
1.99
Gross profit
0.15
2.27
2.54
2.61
0.01
Research and development
7.71
10.3
12
13.5
10.2
21
27.6
8.97
6.32
6.38
General and administrative
2.45
2.76
4.08
3.72
4.23
5.94
13.8
8.43
6.46
8.72
Operating income
-10
-10.8
-13.5
-14.6
-11.8
-24.2
-40.6
-15.8
-12.8
-15.1
Interest expense
2.04
0.85
Interest income
0.1
0.01
4.98
2.37
Other non-operating income
2.93
22.9
-2.29
89.5
Pre-tax income
-9.63
-10.1
-12.7
-14.1
-11.5
5.31
-37.7
5.09
-15.9
75.3
Income tax
1.34
0.4
0.3
0.1
3.18
11.3
Net income to minority interests
-1.2
0.44
-0.04
-0.03
Net income
-11
-10.5
-12.7
-14.4
-11.5
-23
-36.6
5.09
-19.1
64.1
EBITDA
-10
-10.8
-13.5
-14.6
-11.8
-24.1
-40.5
-15.6
-12.6
-15
EPS, basic
0.87
0.79
0.86
0.82
0.56
0.78
-0.94
0.14
-0.48
1.53
EPS, diluted
0.87
0.79
0.86
0.82
0.56
0.78
-0.94
0.14
-0.48
1.50
Shares, basic (weighted)
12.6
13.3
14.9
17.5
20.5
28.5
39
40.3
40.9
41.4
Shares, diluted (weighted)
12.6
13.3
14.9
17.5
20.5
28.5
39
40.6
40.9
42.4
Dividend per share
0.25
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.91
3.97
5
3.33
19.3
77.2
40.5
9.06
54.4
45.9
Short-term investments
2.86
2.86
4.59
3.7
3.3
5.85
3.74
57.7
3.44
5.42
Other current assets
0.2
0.16
0.57
1.04
0.61
1.39
0.54
1.29
2.74
Total current assets
31.2
20.3
31
33.3
40.5
95.3
157
163
143
133
Property, plant and equipment
0.02
0.02
0.02
0.02
0.1
0.4
0.82
0.87
0.7
0.59
Lease right-of-use assets
0.12
0.08
0.53
0.99
0.69
0.41
0.75
Long-term investments
0
0
13.5
1.3
3.93
6.69
2.7
1.81
3.52
8.37
Other non-current assets
0.03
0.03
0.04
Total assets
42.8
38.7
47.4
34.7
44.6
128
162
221
155
231
Accounts payable
1.41
2.72
2.06
2.54
1.7
3.79
4.16
0.55
0.79
0.44
Accrued liabilities
0.53
0.61
0.4
1.08
Deferred revenue
2.16
2.45
2.45
2.7
2.7
1.34
1.35
Short-term debt
2.45
2.7
51
Total current liabilities
3.62
5.17
4.55
5.31
4.54
6.68
5.75
53.2
5.69
19.1
Lease liabilities
0.03
0.4
0.65
0.34
0.16
0.54
Other non-current liabilities
0.39
0.44
0.31
0.27
0.21
0.06
0.06
Total liabilities
16.6
19.5
16.3
15.3
11.8
11.5
10.5
57.7
9.93
31.1
Total debt
11.4
9.66
12.5
0.03
Paid-in capital
71.9
75.2
99.4
100
125
230
314
321
322
323
Retained earnings
-46
-56.5
-69.2
-81.1
-92.6
-115
-163
-158
-177
-123
Other comprehensive income
0.11
0.4
0.7
Shareholders' equity
26.2
19.2
31.1
19.4
32.9
116
152
164
146
200
Minority interests
0.74
-0.66
-0.93
-0.92
Total equity
26.2
19.2
31.1
19.4
32.9
117
151
163
145
200
Total liabilities and equity
42.8
38.7
47.4
34.7
44.6
128
162
221
155
231
Shares outstanding
13.2
13.7
17.4
17.4
23.7
35.3
39.6
40.3
39.9
39.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-11
-10.5
-12.7
-14.4
-11.5
-23
-37.8
5.53
-19.1
64
Depreciation and amortization
0
0.01
0.01
0.01
0.01
0.08
0.06
0.2
0.19
0.12
Stock-based compensation
0.63
1.58
1.55
0.81
0.47
2.7
11.5
4.21
4.05
5.99
Deferred income tax
7.91
Change in payables
-2.23
3.53
1.13
Cash from operations
4.66
-5.83
-14.7
-12.9
-12.4
-21.2
-27.9
-10.3
-8.41
-9.15
Capital expenditures
-0.01
-0.01
-0.01
-0.02
-0.08
-0.38
-0.5
-0.25
-0.02
-0.01
Purchases of investments
-7.01
-3.56
-7.1
-25
-27.2
-18.5
-152
-99.6
-1.31
-9.85
Sales and maturities of investments
5
64.5
39.6
Cash from investing
-16
4.3
-7
11.3
4.63
-23.8
30.2
-73
106
5.44
Debt repaid
-50
-49.6
Stock issued
10.6
0.03
21.7
10.6
11.5
2.43
Share buybacks
-2.48
-4.74
Cash from financing
12
1.59
22.7
23.8
103
10.8
52
-52
-4.74
Exchange rate effect
0.01
0.01
0.03
0.01
-0.01
0
-0.06
-0.05
-0
-0.03
Net change in cash
0.69
0.06
1.03
-1.67
16
57.9
13
-31.4
45.4
-8.47
Free cash flow
4.65
-5.84
-14.7
-13
-12.5
-21.6
-28.4
-10.5
-8.43
-9.15
Interest paid
0.57
2.32
Income taxes paid
0.4
0.3
0.56
1.84
2.32
3.32
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.73 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Effective tax rate
20.6%
Income tax / pre-tax income, when pre-tax income is positive.
Return on assets (ROA)
47.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue CAGR, 3y
-9.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-5.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS CAGR, 5y
21.8%
Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
36.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
9.6%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
43.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
48.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
12.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
38.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
15.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.98x
Current assets / current liabilities.
Quick ratio
1.50x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.50x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
14.1%
Total liabilities / total assets.
Working capital
$42.7M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
FCF conversion
-3.0%
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$4.11
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/E
1.13x
Market cap / net income. Only when net income is positive.
FCF yield
-2.7%
Free cash flow / market cap.
Earnings yield
88.9%
Net income / market cap (the inverse of P/E).
What was ORAMED PHARMACEUTICALS INC.'s revenue in fiscal 2025?
ORAMED PHARMACEUTICALS INC. reported revenue of $2.0M for fiscal 2025.
Was ORAMED PHARMACEUTICALS INC. profitable in fiscal 2025?
Yes. Net income was $64.1M, a net margin of 3,202.5%.
How much free cash flow did ORAMED PHARMACEUTICALS INC. generate in fiscal 2025?
Cash from operations of $9.1M minus capital expenditures of $9.0K left free cash flow of -$9.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.